Intellectual property issues in a clinical trial: a corporate perspective.
作者信息
Fersko R S, Connolly M J
机构信息
Tanner Propp & Fersko, New York, New York 10016.
出版信息
Qual Assur. 1992 Jun;1(3):237-48.
PMID:1344679
Abstract
摘要
相似文献
1
Intellectual property issues in a clinical trial: a corporate perspective.
Qual Assur. 1992 Jun;1(3):237-48.
2
Research interactions between industry and academia: a corporate perspective.
Physiologist. 1996 Jun;39(3):81, 90-2.
3
Grant proposal reviewer says he would have scored proposal lower due to conflict of interest.
Hum Res Rep. 2004 Dec;19(12):8.
4
FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
AIDS Treat News. 1998 Mar 6(No 290):8.
5
Regulating scientific research: intellectual property rights and the norms of science.
Northwest Univ Law Rev. 1999 Fall;94(1):77-152.
6
Researcher said his colleague should have revealed possible conflicts of interest.
Hum Res Rep. 2005 Jan;20(1):8.
7
NerveCenter: Office of Inspector General warns NIH on lax COI oversight as many academic medical centers look inward.
Ann Neurol. 2010 Mar;67(3):A7-A10. doi: 10.1002/ana.22026.
8
Razing the tollbooths. A call for restricting patents on basic biomedical research.
Sci Am. 2003 Apr;288(4):37.
9
March-in rights under the Bayh-Dole Act: the NIH's paper tiger?
Seton Hall Law Rev. 2013 Nov 1;43(4):1403-32.
10
Is academic medicine for sale?
N Engl J Med. 2000 Aug 17;343(7):509; author reply 510.
Zotero 插件